Short Interest in Shionogi & Co., Ltd. (OTCMKTS:SGIOY) Declines By 19.2%

Shionogi & Co., Ltd. (OTCMKTS:SGIOY) saw a significant decline in short interest in the month of January. As of January 31st, there was short interest totalling 185,700 shares, a decline of 19.2% from the January 15th total of 229,900 shares. Based on an average daily trading volume, of 414,100 shares, the days-to-cover ratio is currently 0.4 days.

Shionogi & Co., Ltd. Stock Performance

Shares of SGIOY opened at $7.06 on Monday. The stock has a market cap of $12.01 billion, a PE ratio of 12.34, a price-to-earnings-growth ratio of 2.36 and a beta of 0.23. Shionogi & Co., Ltd. has a fifty-two week low of $6.22 and a fifty-two week high of $9.11. The firm’s 50-day simple moving average is $7.08 and its two-hundred day simple moving average is $8.30.

Shionogi & Co., Ltd. (OTCMKTS:SGIOY) last announced its quarterly earnings data on Friday, January 31st. The company reported $0.16 earnings per share for the quarter. Shionogi & Co., Ltd. had a net margin of 35.53% and a return on equity of 11.95%. Equities research analysts predict that Shionogi & Co., Ltd. will post 0.66 EPS for the current year.

Shionogi & Co., Ltd. Company Profile

Shionogi & Co, Ltd. engages in the research, development, manufacture, and distribution of pharmaceuticals, diagnostic reagents, and medical devices in Japan. It offers Fetroja, a multidrug-resistant for gram-negative bacterial infection treatment; Cabenuva and Apretude an anti-HIV and HIV prophylactic drug; Xocova an oral COVID-19 treatment drug; Finibax a carbapenem antibiotic; Xofluza, an influenza antiviral drug; and Tivicay, an anti-HIV drug.